Your pituitary still makes growth hormone. That's the part most people get wrong. The practitioner corpus is consistent: as the GH axis ages, the gland keeps producing — it loses the ability to release in the sharp, timed pulses your tissues are built to respond to. The hormone is there. The signal isn't. That distinction is the entire reason this Path doesn't start with exogenous HGH, and it's why everything in Module 3 sits on a secretagogue base instead of a synthetic one.
This matters specifically for recomposition. Growth hormone is the master anabolic and lipolytic hormone — it partitions calories toward muscle and away from adipose, accelerates connective-tissue repair between training sessions, and drives the overnight recovery window where slow-wave sleep, IGF-1 production, and tissue remodeling actually happen. When the pulse flattens, you don't stop building muscle. You stop building it efficiently. Recovery gets longer. Body fat gets stickier. The same training load produces less.
What "pulsatile" actually means
Natural GH release is not a continuous infusion. The practitioner consensus describes it as a precisely timed sequence — sharp pulses every few hours, with the largest spike during deep sleep, gated by a feedback loop between the hypothalamus (GHRH on, somatostatin off) and the pituitary somatotrophs. Your tissues respond to the shape of that pulse, not the area under the curve. Flat exposure desensitizes receptors. Pulsatile exposure sensitizes them. This is why exogenous HGH — which delivers a flat, unnatural bolus — produces water retention, joint pain, insulin resistance, and over time, suppression of your own pituitary output. You bought the molecule and lost the rhythm.
Secretagogues work upstream. They don't supply the hormone — they restore the signal that releases it. Two receptor families do the work:
- GHRH receptor (growth hormone-releasing hormone) — the baseline amplifier. Tells the pituitary "release whatever you've made." CJC-1295, Sermorelin, and Tesamorelin act here.
- Ghrelin receptor / GHS-R — the pulse trigger. Tells the pituitary to fire and suppresses somatostatin, the brake that normally damps GH release. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin act here.
The dual mechanism is the leverage. A ghrelin-receptor agonist alone fires a pulse but somatostatin clamps it. A GHRH alone amplifies a signal that somatostatin can still suppress. Combine them and you get amplification, pulse, and brake-release in the same window — the practitioner corpus calls this synergistic, with combined output that exceeds either compound alone.
Why this stack, and not the others
Of the GHRP family, the practitioner consensus consistently lands on Ipamorelin as the cleanest option for a recomposition Path. GHRP-2 and GHRP-6 release more GH per dose but carry spillover — GHRP-6 drives strong hunger (useful in a bulk, problematic in a recomp), GHRP-2 elevates cortisol and prolactin. Ipamorelin produces a sharp pulse with no cortisol or prolactin spillover, no meaningful hunger response, and a tolerability profile that holds up over long protocols. That clean profile is why it pairs with CJC-1295 in the most widely recommended GH secretagogue combination among leading practitioners.
On the GHRH side, the substrate splits between CJC-1295 with DAC (8+ day half-life, once-weekly dosing, sustained GHRH tone) and CJC-1295 without DAC / Mod GRF 1-29 (~30 min half-life, multiple daily doses, more pulsatile). The case for DAC is convenience and a steady baseline that lets the Ipamorelin pulse ride on top. The case against DAC, from a subset of the practitioner corpus, is that sustained GHRH tone may flatten the very pulsatility you're trying to preserve and shouldn't be run beyond 4-5 weeks continuously. Both camps agree the Ipamorelin pulse is the active ingredient; the GHRH choice is about how to amplify it.
This Path uses the DAC version for Phase 1 (Weeks 1-4) to lock in baseline, then transitions to no-DAC for Phase 2 to protect long-term pulsatility. Module 3 covers the transition.
Protocol — Phase 1 GH axis restoration (Weeks 1-4)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| CJC-1295 DAC | 2 mg | SubQ | Once weekly, any time of day | 🟢 Expert | 8+ day half-life — establishes sustained GHRH baseline. Inject same day each week. |
| Ipamorelin | 100–200 mcg | SubQ | 2× daily — morning fasted + before bed | 🟢 Expert | Bedtime dose 2+ hours after last meal — stacks with natural sleep-time GH surge. Sharp pulse, no cortisol/prolactin. |
| Tesamorelin (optional swap for CJC-1295 DAC) | 200–500 mcg | SubQ | Daily, evening | 🔵 Clinical | FDA-approved for lipodystrophy. Use this instead of CJC-1295 if visceral fat is the dominant recomposition target. |
| GHRP-6 (alternate GHRP) | 100–150 mcg | SubQ | 1–4× daily | 🟢 Expert | Higher GH release than Ipamorelin but drives hunger — only swap in if you're in a deliberate surplus, not a recomp. |
| IGF-1 LR3 | [practitioner corpus thin on Phase 1 dosing — track and report] | — | — | 🟣 Experimental | Reserved for advanced cycles per the substrate; not part of Phase 1 baseline. |
Insulin caveat — read before starting. The substrate is explicit: GH naturally antagonizes insulin. If your baseline fasting insulin is elevated or you're insulin-resistant going in, GH secretagogues can worsen the dysfunction before improving it. Pull fasting insulin and HbA1c in the baseline labs from Module 6 before you start. If insulin is above ~10 µIU/mL, address that first — the rest of the Path won't compound on a broken substrate.
What you should feel
Substrate-cited milestones — these are the markers the practitioner corpus tracks:
- Nights 1–7: Deeper sleep, more REM, more vivid dreams within the first week. This is the most reliable early signal that the Ipamorelin pulse is landing in the natural overnight GH window.
- Weeks 2–3: Faster recovery between training sessions. The training stimulus you used to need 72 hours to repeat starts feeling repeatable in 48.
- Weeks 3–4: Visible skin quality improvement (the substrate cites this as a consistent observational marker), slightly tighter midsection from early visceral fat mobilization, mild but durable energy lift through the day.
- Week 4 labs: IGF-1 should move. The practitioner consensus treats IGF-1 as the proxy for total GH activity; this is the marker you pull at Week 4 to confirm the axis is responding before layering Phase 2.
What's NOT happening yet
- You are not gaining significant lean mass in Weeks 1–4. The GH axis is the upstream lever, not the hypertrophy driver. Phase 2 (Module 4) layers the building-block compounds. Phase 1 is signal restoration.
- You will not see scale weight change in either direction. GH-mediated recomposition is a slow body-composition shift, not a weight-loss intervention. The substrate is clear that GH partitions calories — it doesn't create a deficit.
- You are not experiencing the bone-growth side effects of supraphysiologic HGH. Secretagogues operate within the feedback loop. The jaw/brow/organ-growth concerns the substrate flags around exogenous HGH are not in play at these doses on this mechanism.
- You should not need any aromatase inhibitor, ancillary, or thyroid support yet. The Phase 1 stack is intentionally clean. If you're stacking from another protocol, Module 5 covers integration.
The practitioner corpus describes this protocol. Track IGF-1 at Week 4 and adjust before Phase 2.